RecruitingPhase 2NCT06493760

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Enrollment

130 participants

Start Date

Sep 3, 2024

Study Type

INTERVENTIONAL

Conditions

Metastatic Colorectal Cancer

Summary

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called SSGJ-707 in people with colorectal cancer that has spread to other parts of the body (metastatic) and has stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older with metastatic colorectal cancer confirmed by biopsy - You are in good physical condition (ECOG 0–1) - Your expected survival is at least 12 weeks - You have received prior standard treatments **You may NOT be eligible if...** - You have active, uncontrolled cancer in the brain or spinal cord - You have unresolved side effects from prior cancer treatments - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You have active infections or autoimmune conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.